Last updated: 2026-09-16 13:20:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Alpha Tau Medical Ltd. (DRTS) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $14.95, with a market capitalisation of $1.33B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3.43 to $15.17. This page covers its latest market performance, valuation, price trends and company information.
$1.33B | |
$14.56 | |
$20.65 | |
$1.75 | |
$14.87 | |
9.02K | |
666.23K | |
-- | |
$15.17 | |
$3.43 | |
-- | |
-- |
Alpha Tau Medical Ltd. (DRTS) is trading at $14.95 in pre-market trading as of 2026-09-16 13:18:00, up 0.54% ($0.08) from the previous close of $14.87
Pre-market trading shows how investors are pricing DRTS before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Alpha Tau Medical Ltd. (DRTS) moved from $15.03 to $14.95, representing a decline of 0.53% ($0.08).
The stock traded between $13.80 and $15.17 during the period. The latest price is near the upper end of the 7-day range, indicating moderate downward.
The average daily volume was 484.99 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 98.1%
DRTS is currently trading at $14.95, placing it 98.1% of the way from its 52-week low of $3.43 to its 52-week high of $15.17. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.
| Employees | 121 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Alpha Tau Medical Ltd. (DRTS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.